A new study attempted to quantify the economic burden of early progression in patients with newly-diagnosed multiple myeloma. READ MORE
Heart failure, angina, and other cardiovascular adverse events occur more frequently in patients with relapsed multiple myeloma receiving a conventional therapy.
Results of a recent study showed that the prognostic implications of patient-specific and tumor biological features vary significantly across age-groups of patients with multiple myeloma.
A recent study found that a significant number of patients with multiple myeloma harbor potentially actionable oncogenic molecular alterations, prompting a need for novel precision medicine approaches.
A recent study found that continued therapy with a combination regimen until disease progression improves outcomes in patients with newly diagnosed multiple myeloma who are not eligible for ASCT.